Clinical Trial Update: AZD2171 and Pemetrexed Disodium in Treating Patients With Relapsed Non-Small Cell Lung Cancer [Phase 2]

View source ↗

Summary

Phase 2 study evaluating the combination of AZD2171 (cediranib) and pemetrexed disodium in patients with relapsed non-small cell lung cancer has completed with …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• AZD2171 (cediranib) (cediranib)
• Pemetrexed disodium (Alimta) (pemetrexed disodium)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Recurrent Non-small Cell Lung Cancer | Phase 2 | Status: COMPLETED | Results posted: 2014-09-22